Literature DB >> 15334546

Interstitial deletions including chromosome 3 common eliminated region 1 (C3CER1) prevail in human solid tumors from 10 different tissues.

Thorgunnur Eyfjord Petursdottir1, Unnur Thorsteinsdottir, Jon Gunnlaugur Jonasson, Pall Helgi Moller, Chen Huiping, Johannes Bjornsson, Valgardur Egilsson, Stefan Imreh, Sigurdur Ingvarsson.   

Abstract

A human chromosomal segment regularly lost during tumor formation of microcell hybrids in SCID mice has been mapped to 3p21.3. This segment, called chromosome 3 common eliminated region 1 (C3CER1, also referred to as CER1), may harbor multiple tumor-suppressor genes. Because it was found that similar regions were eliminated in an inter- and intraspecies system and in two tumor types (mouse fibrosarcoma and human renal cell carcinoma), we hypothesized that the importance of C3CER1 would transgress tissue specificity, that is, it could occur in tumors derived from multiple tissues. To evaluate the loss of C3CER1 in various human tumor types, we conducted loss of heterozygosity (LOH) analysis of 576 human solid tumors from 10 different tissues and compared the frequency of deletion in the C3CER1 area to that in two other regions on 3p: the FHIT/FRA3B region, at 3p14.2, and the VHL region, at 3p25.3. Deletions were detected in the C3CER1 region in 83% of informative tumors. Half (47%) the LOH-positive tumors showed LOH at all informative markers, indicating a large deletion. The other half (53%) had a discontinuous LOH pattern, suggesting interstitial deletions or breakpoints. The proportion of tumors with C3CER1 deletions was high in all tumor types investigated, ranging from 70% to 94%, except for the soft-tissue sarcomas (40%). In the VHL and FHIT regions, deletions were observed in 73% and 43%, respectively, of the tumors. Of the three 3p regions analyzed, the highest deletion frequency was observed in the C3CER1 region. Furthermore, we demonstrated that the interstitial deletions including C3CER1 prevail over 3p14.2-pter losses in solid tumors. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334546     DOI: 10.1002/gcc.20072

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  Diagnostic value of abnormal chromosome 3p genes in small-cell lung cancer.

Authors:  Chunxu Ma; Jihua Zhao; Ying Wu; Jun Wang; Hao Wang
Journal:  Oncol Lett       Date:  2022-05-16       Impact factor: 3.111

2.  Genomic changes in progression of low-grade gliomas.

Authors:  Ahmed Idbaih; Rosana Carvalho Silva; Emmanuelle Crinière; Yannick Marie; Catherine Carpentier; Blandine Boisselier; Sophie Taillibert; Audrey Rousseau; Karima Mokhtari; François Ducray; Joelle Thillet; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2008-07-11       Impact factor: 4.130

3.  The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development.

Authors:  Tyson V Sharp; Ahmad Al-Attar; Daniel E Foxler; Li Ding; Thomas Q de A Vallim; Yining Zhang; Hala S Nijmeh; Thomas M Webb; Andrew G Nicholson; Qunyuan Zhang; Aldi Kraja; Ian Spendlove; John Osborne; Elaine Mardis; Gregory D Longmore
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-05       Impact factor: 11.205

4.  LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription.

Authors:  Tyson V Sharp; Fernando Munoz; Dimitra Bourboulia; Nadege Presneau; Eva Darai; Hsei-Wei Wang; Mark Cannon; David N Butcher; Andrew G Nicholson; George Klein; Stephan Imreh; Chris Boshoff
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-12       Impact factor: 11.205

Review 5.  Engineered Swine Models of Cancer.

Authors:  Adrienne L Watson; Daniel F Carlson; David A Largaespada; Perry B Hackett; Scott C Fahrenkrug
Journal:  Front Genet       Date:  2016-05-09       Impact factor: 4.599

Review 6.  The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform.

Authors:  Kyle M Schachtschneider; Regina M Schwind; Jordan Newson; Nickolas Kinachtchouk; Mark Rizko; Nasya Mendoza-Elias; Paul Grippo; Daniel R Principe; Alex Park; Nana H Overgaard; Gregers Jungersen; Kelly D Garcia; Ajay V Maker; Laurie A Rund; Howard Ozer; Ron C Gaba; Lawrence B Schook
Journal:  Front Oncol       Date:  2017-08-23       Impact factor: 6.244

7.  LIMD1 is a survival prognostic marker of gastric cancer and hinders tumor progression by suppressing activation of YAP1.

Authors:  Di Zhang; Song Li; Wenbin Yu; Cheng Chen; Teng Liu; Yiting Sun; Zeyi Zhao; Lian Liu
Journal:  Cancer Manag Res       Date:  2018-10-09       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.